共 50 条
- [1] LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALSJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 55 - 55Ray, Kausik KumarVallejo-Vaz, AntonioGinsberg, HenryDavidson, MichaelEckel, Robert H.Lee, VeronicaBessac, LaurencePordy, RobertLetierce, AlexiaCannon, Christopher
- [2] Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab TrialsJOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (18):Vallejo-Vaz, Antonio J.Ginsberg, Henry N.Davidson, Michael H.Eckel, Robert H.Cannon, Christopher P.Lee, L. VeronicaBessac, LaurencePordy, RobertLetierce, AlexiaRay, Kausik K.
- [3] Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlATHEROSCLEROSIS, 2019, 288 : 85 - 93Vallejo-Vaz, Antonio J.Ray, Kausik K.Ginsberg, Henry N.Davidson, Michael H.Eckel, Robert H.Lee, L. VeronicaBessac, LaurencePordy, RobertLetierce, AlexiaCannon, Christopher P.
- [4] Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular RiskJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 439 - 440Zafar, KamranInayat, Maimoona
- [5] Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk ReplyJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 440 - 440Silverman, Michael G.Im, KyungahSabatine, Marc S.
- [6] RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROLJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1867 - 1867Cannon, Christopher P.Ginsberg, HenryRay, KausikDavidson, MichaelPordy, RobertBessac, LaurenceMinini, PascalEckel, Robert
- [7] Comparison of Low-density Lipoprotein Cholesterol Threshold Attainment With Alirocumab versus Ezetimibe Treatment in the ODYSSEY ProgramCIRCULATION, 2016, 134Cannon, Christopher P.Cariou, BertrandValcheva, VelichkaGuillonneau, SophieIorga, Serban R.Davidson, Michael H.
- [8] Is lower low-density lipoprotein cholesterol associated with lower androgen and erectile dysfunction in men?NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2018, 28 (12) : 1304 - 1310Chen, C.Zhai, H.Huang, G.Cheng, J.Xia, F.Zhao, L.Chen, Y.Chen, Y.Han, B.Li, Q.Jiang, B.Wang, N.Lu, Y.
- [9] Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk Where DoWe Stand?JAMA CARDIOLOGY, 2017, 2 (09) : 937 - 938Lloyd-Jones, Donald M.
- [10] Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialEUROPEAN HEART JOURNAL, 2020, 41 (44) : 4245 - 4255Szarek, MichaelBittner, Vera A.Aylward, PhilipBaccara-Dinet, MarieBhatt, Deepak L.Diaz, RafaelFras, ZlatkoGoodman, Shaun G.Halvorsen, SigrunHarrington, Robert A.Jukema, J. WouterMoriarty, Patrick M.Pordy, RobertRay, Kausik K.Sinnaeve, PeterTsimikas, SotiriosVogel, RobertWhite, Harvey D.Zahger, DoronZeiher, Andreas M.Steg, Ph GabrielSchwartz, Gregory G.